Turn Therapeutics is starting a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation for the treatment of moderate-to-severe eczema (atopic dermatitis).
Patient dosing commenced on July 11, 2025 in Dallas, TX, the Company reports.
This clinical trial builds on in vivo confirmation of the formulation’s potent immunological inhibition of key eczema-related cytokines, including interleukin (IL)-36.
It also marks the first clinical trial of a topical IL-36 inhibitor.
Turn Therapeutics is targeting enrollment of 114 patients with moderate-to-severe eczema in the trial, which will include an eight-week treatment course. The study’s primary efficacy endpoint is the change in patients’ Eczema Area and Severity Index (EASI) scores from baseline, with secondary endpoints that include Investigators Global Assessment (IGA) and Max-Itch assessment scores. Top-line results are expected by the end of 2025.
Earlier studies have demonstrated the topical GX-03 formulation—previously used in the company’s advanced wound care product Hexagen—has the ability to inhibit IL-36 alpha, IL-36 gamma, and IL-4.
The formula also has shown significant inhibitory activity against IL-31.
It has previously been cleared by the U.S. FDA for acute and chronic wound care indications. Turn is pursuing expanded indications for the formula, including as a drug treatment for both moderate-to-severe eczema and onychomycosis.
